Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance

Dagmar Busse, F. Michael Yakes, Anne E.G. Lenferink, Carlos L. Arteaga

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Tyrosine kinases play a role in normal cellular regulatory processes. However, aberrant tyrosine kinase activity can lead to cellular transformation and can be causally associated with tumor maintenance and progression. In the last few years, high-throughput screening and the use of combinatorial, computational, and medicinal chemistry have led to the identification of small molecules that compete with the adenosine triphosphate binding site of the catalytic domain of several oncogenic tyrosine kinases. Some of these compounds are highly specific to a single tyrosine kinase, while others can inhibit several homologous kinase pockets simultaneously. At a practical level, the relative promiscuity of these inhibitors against more than one oncogenic tyrosine kinase may have clinical merit as well as implications for host tissue toxicity. Many of these small molecules are in different stages of preclinical and clinical development against several solid tumors and will be discussed.

Original languageEnglish (US)
Pages (from-to)47-55
Number of pages9
JournalSeminars in Oncology
Volume28
Issue number5 SUPPL. 16
StatePublished - Nov 27 2001

Fingerprint

Drug Resistance
Protein-Tyrosine Kinases
Pharmaceutical Chemistry
Catalytic Domain
Neoplasms
Phosphotransferases
Adenosine Triphosphate
Binding Sites
Maintenance

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Tyrosine kinase inhibitors : Rationale, mechanisms of action, and implications for drug resistance. / Busse, Dagmar; Yakes, F. Michael; Lenferink, Anne E.G.; Arteaga, Carlos L.

In: Seminars in Oncology, Vol. 28, No. 5 SUPPL. 16, 27.11.2001, p. 47-55.

Research output: Contribution to journalArticle

Busse, Dagmar ; Yakes, F. Michael ; Lenferink, Anne E.G. ; Arteaga, Carlos L. / Tyrosine kinase inhibitors : Rationale, mechanisms of action, and implications for drug resistance. In: Seminars in Oncology. 2001 ; Vol. 28, No. 5 SUPPL. 16. pp. 47-55.
@article{515fb239e7664905ad583d3ac08e6005,
title = "Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance",
abstract = "Tyrosine kinases play a role in normal cellular regulatory processes. However, aberrant tyrosine kinase activity can lead to cellular transformation and can be causally associated with tumor maintenance and progression. In the last few years, high-throughput screening and the use of combinatorial, computational, and medicinal chemistry have led to the identification of small molecules that compete with the adenosine triphosphate binding site of the catalytic domain of several oncogenic tyrosine kinases. Some of these compounds are highly specific to a single tyrosine kinase, while others can inhibit several homologous kinase pockets simultaneously. At a practical level, the relative promiscuity of these inhibitors against more than one oncogenic tyrosine kinase may have clinical merit as well as implications for host tissue toxicity. Many of these small molecules are in different stages of preclinical and clinical development against several solid tumors and will be discussed.",
author = "Dagmar Busse and Yakes, {F. Michael} and Lenferink, {Anne E.G.} and Arteaga, {Carlos L.}",
year = "2001",
month = "11",
day = "27",
language = "English (US)",
volume = "28",
pages = "47--55",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 16",

}

TY - JOUR

T1 - Tyrosine kinase inhibitors

T2 - Rationale, mechanisms of action, and implications for drug resistance

AU - Busse, Dagmar

AU - Yakes, F. Michael

AU - Lenferink, Anne E.G.

AU - Arteaga, Carlos L.

PY - 2001/11/27

Y1 - 2001/11/27

N2 - Tyrosine kinases play a role in normal cellular regulatory processes. However, aberrant tyrosine kinase activity can lead to cellular transformation and can be causally associated with tumor maintenance and progression. In the last few years, high-throughput screening and the use of combinatorial, computational, and medicinal chemistry have led to the identification of small molecules that compete with the adenosine triphosphate binding site of the catalytic domain of several oncogenic tyrosine kinases. Some of these compounds are highly specific to a single tyrosine kinase, while others can inhibit several homologous kinase pockets simultaneously. At a practical level, the relative promiscuity of these inhibitors against more than one oncogenic tyrosine kinase may have clinical merit as well as implications for host tissue toxicity. Many of these small molecules are in different stages of preclinical and clinical development against several solid tumors and will be discussed.

AB - Tyrosine kinases play a role in normal cellular regulatory processes. However, aberrant tyrosine kinase activity can lead to cellular transformation and can be causally associated with tumor maintenance and progression. In the last few years, high-throughput screening and the use of combinatorial, computational, and medicinal chemistry have led to the identification of small molecules that compete with the adenosine triphosphate binding site of the catalytic domain of several oncogenic tyrosine kinases. Some of these compounds are highly specific to a single tyrosine kinase, while others can inhibit several homologous kinase pockets simultaneously. At a practical level, the relative promiscuity of these inhibitors against more than one oncogenic tyrosine kinase may have clinical merit as well as implications for host tissue toxicity. Many of these small molecules are in different stages of preclinical and clinical development against several solid tumors and will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=0035173157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035173157&partnerID=8YFLogxK

M3 - Article

C2 - 11706396

AN - SCOPUS:0035173157

VL - 28

SP - 47

EP - 55

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 16

ER -